Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies

Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment

(2015) Haeng Jung Lee et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2′-deoxy-5-fluorouridine into DNA

(2015) KAZUKI SAKAMOTO et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Involvement of Concentrative Nucleoside Transporter 1 in Intestinal Absorption of Trifluridine Using Human Small Intestinal Epithelial Cells

(2015) Koichi Takahashi et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Trifluridine Induces p53-Dependent Sustained G2 Phase Arrest with Its Massive Misincorporation into DNA and Few DNA Strand Breaks

(2015) K. Matsuoka et al.   MOLECULAR CANCER THERAPEUTICS

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

(2015) Robert J. Mayer et al.   NEW ENGLAND JOURNAL OF MEDICINE

The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells

(2014) Kaamar Azijli et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Standing the test of time: targeting thymidylate biosynthesis in cancer therapy

(2014) Peter M. Wilson et al.   Nature Reviews Clinical Oncology

Radiosensitization by Thymidine Phosphorylase Inhibitor in Thymidine Phosphorylase Negative and Overexpressing Bladder Cancer Cell Lines

(2014) Maha El-Naggar et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

Novel Developments in the Use of Antimetabolites

(2014) Godefridus J. Peters   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models

(2014) NOZOMU TANAKA et al.   ONCOLOGY REPORTS

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours

(2012) T Doi et al.   BRITISH JOURNAL OF CANCER

TAS-102: more than an antimetabolite

(2012) Godefridus J Peters et al.   LANCET ONCOLOGY

TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial

(2012) Takayuki Yoshino et al.   LANCET ONCOLOGY

Thymidine phosphorylase in cancer cells stimulates human endothelial cell migration and invasion by the secretion of angiogenic factors

(2011) I V Bijnsdorp et al.   BRITISH JOURNAL OF CANCER

Platelet-derived endothelial cell growth factor/thymidine phosphorylase inhibitor augments radiotherapeutic efficacy in experimental colorectal cancer

(2011) Tomohiko Miyatani et al.   CANCER LETTERS

Deoxyribose Protects Against Rapamycin-Induced Cytotoxicity in Colorectal Cancer Cells In Vitro

(2011) I. V. Bijnsdorp et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks

(2011) NORIHIKO SUZUKI et al.   Experimental and Therapeutic Medicine

Accumulation of thymidine-derived sugars in thymidine phosphorylase overexpressing cells

(2010) I.V. Bijnsdorp et al.   BIOCHEMICAL PHARMACOLOGY

Trifluorothymidine Resistance Is Associated with Decreased Thymidine Kinase and Equilibrative Nucleoside Transporter Expression or Increased Secretory Phospholipase A2

(2010) Olaf H. Temmink et al.   MOLECULAR CANCER THERAPEUTICS

Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines

(2009) Irene V. Bijnsdorp et al.   CANCER SCIENCE

Phase I Clinical Study of Three Times a Day Oral Administration of TAS-102 in Patients with Solid Tumors

(2008) Michael J. Overman et al.   CANCER INVESTIGATION

Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent

(2008) I.V. Bijnsdorp et al.   CANCER SCIENCE

Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors

(2008) Michael J. Overman et al.   INVESTIGATIONAL NEW DRUGS